Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses the challenge of prior authorizations.
Transcript:
How would you like to see prior authorizations change to reduce the burdens for patients and physicians?
When we talk to physicians that treat patients with many of the chronic, complex diseases that make up our community, they tell us that it’s maddening the diversity of prior authorization forms. Unfortunately, many of them tell us it’s only the offices that devote full-time staff to prior authorization forms where you see patients getting the drugs that their physicians prescribed.
We think that that’s just an absolutely ridiculous system where patients are only receiving the drugs their doctors prescribed because there’s staff on hand to process forms. So, what we’d like to see done is have more legislation pass that requires uniformity of prior authorization forms. Florida took a massive step forward in doing that last year, but I think there’s still more reform efforts that need to be undertaken.
I think we need to apply some penalties to that type of legislation, so that if insurers are found to not be in compliance with standardization of prior authorization forms that there’s some sort of monetary penalty for doing that, per instance, not for a totality. It’s really critical that insurers are talking to physicians. I think that physicians need to be engaged really on a focus-group level in state—specifically in-state, talking with the specialists in-state or even general practitioners to some degree—to get an understanding of what are the major hurdles and barriers in the prior authorization forms that currently exist.
I think that a lot of times there are no answers to those questions and those conversations haven’t been had. They need to occur. We’d love to help them occur, we’d love to connect insurers in states with specialty physicians that we know have had difficulty, and their patients have had difficulty, with processing prior authorization forms.
But we should never live in a world where a person with a chronic disease can’t get access to a drug because their doctor or staff hasn’t or can’t fill out a form correctly or doesn’t have the time to fill out a form because it’s so onerous.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
2 Commerce Drive
Cranbury, NJ 08512